Topic - Abbott

avatar
General news, Biosciences, Finance

Nanosphere Eyes $100M IPO

Personalized medicine startup files for $100M initial public offering, but analyst says move could be prelude to an acquisition by a major life sciences company.
avatar
Biosciences

Genentech Hit Three Ways

Cabilly patent overturned; FDA wants new Xolair warning; Avastin sales threatened.
avatar
Biosciences

Pharma Shops Biotech at JPMorgan Conference

JPMorgan's annual healthcare confab. highlights trends and themes shaping the sector.
avatar
Biosciences

Picking Medtronic CEO’s Brain

Investors look to get insight on the medical device industry’s coming year with top chief Art Collins.
avatar
Biosciences

Building the Bionic Man

Year in Review: Innovation and controversy defined the medical technology industry.
avatar
Biosciences

Xtent Plans $103M IPO

The heart device company hopes to raise funds to pump into drug-eluting stents.
avatar
Biosciences

Abbott Holds Back AIDS Drug

Humanitarian organization appeals to Abbott and looks for help from generic drugmakers.
avatar
Biosciences

Stent Carries 2 Drugs at Once

Conor Medsystems implants the first patient with a dual-drug heart device.
avatar
Biosciences

Drugs & Devices: Flowing Blood

Abbott’s diagnostic lung cancer deal; cataract removal device study to start.
avatar
General news, Biosciences

FTC OK Ends Guidant Deal Saga

Boston Scientific gets U.S. government clearance to acquire troubled heart device maker Guidant.
avatar
Biosciences

Drugs & Devices: Guidant in EU

Europe probes Boston-Guidant deal; Inamed’s outperforming wrinkle filler; polls shows Americans like techy medicine.
avatar
Biosciences

Guidant Late on Repair Alert

Inspectors say heart device maker failed to report in a timely manner on repair work for certain defibrillator products.
avatar
Biosciences, Finance

Drugs & Devices: Guidant Deal

BSX files for merger clearance; Allergan extends Inamed offer; NUCRYST wound dressing goes to Europe.
avatar
Biosciences

Guidant Picks Boston for $27B

Heart device maker terminates agreement with Johnson & Johnson after the deadline expires for raised bid.
avatar
Biosciences, Finance

Fat-Blocker Pill OK’d by Panel

An FDA advisory panel recommends Glaxo’s drug Alli become the first over-the-counter weight-loss drug.
avatar
General news, Biosciences

Q&A: GTC’s Geoffrey Cox

CEO of GTC Biotherapeutics says his firm is rearing transgenic goats that will lead to a drug to treat blood-clotting problems.
avatar
Biosciences

Drugs & Devices: Rigel Rebound

Rigel stock on the upswing; Salix inks $37M-license deal; Abbott’s bipolar drug approved.
avatar
Security, Media

Texas Sues Sony Over Spyware

Texas suit, and another by the EFF, allege Sony BMG installed spyware through its CDs.
avatar
Biosciences

Abbott in $255M Humira Deal

The health care company agrees to pay Cambridge Antibody Technology the sum instead of future royalties.
avatar
General news, Biosciences

Drugs & Devices: ‘Manograms’

Manograms for prostate cancer; Abbott glucose meters can be misused; cancer diagnostics growing to $7.4B.
Page 1 of 2
1 2 >